Carmen Fava

Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study

Francesco Passamonti, Chiara Cattaneo, Luca Arcaini et al. · The Lancet Haematology · 2020 · 551 citations · Full text

Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With Imatinib

Carlo Gambacorti‐Passerini, Laura Antolini, François‐Xavier Mahon et al. · JNCI Journal of the National Cancer Institute · 2011 · 424 citations · Full text

Nilotinib for the frontline treatment of Ph+ chronic myeloid leukemia

Gianantonio Rosti, Francesca Palandri, Fausto Castagnetti et al. · Blood · 2009 · 210 citations · Full text

Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study

Srđan Verstovšek, Aaron T. Gerds, Alessandro M. Vannucchi et al. · The Lancet · 2023 · 164 citations

Hematological Malignancy, Bone Marrow Failure, Momelotinib Versus Danazol +6

Chronic fatigue is the most important factor limiting health-related quality of life of chronic myeloid leukemia patients treated with imatinib

Fabio Efficace, Michele Baccarani, Massimo Breccia et al. · Leukemia · 2013 · 135 citations

Hematological Malignancy, Quality Of Life, Important Factor +11